Risk of a secondary neoplasm associated with radiation therapy
| . | Number of patients (%) . | Number of SN . | Cumulative incidence after 15 y (95% CI) . |
|---|---|---|---|
| CRT (frontline therapy) | P = .044 | ||
| None | 1388 (27.7) | 7 | 1.0% (0%-2.1%) |
| ≥ 12 Gy | 3618 (72.3) | 39 | 3.3% (1.1%-5.6%) |
| 12 Gy | 2015 | 11 | 1.6% (0-3.4%) |
| ≥ 18 Gy | 1603 | 28 | 3.3% (0.9-5.6%) |
| CRT (+ relapse therapy) | P = .048 | ||
| None | 1140 (22.8) | 7 | 1.2% (0.2-2.3%) |
| ≥ 12 Gy | 3866 (77.2) | 45 | 3.5% (1.5%-5.5%) |
| 12 Gy | 1779 | 11 | 1.7% (0.1-3.4%) |
| ≥ 18 Gy | 2087 | 34 | 3.2% (1.1-5.3%) |
| . | Number of patients (%) . | Number of SN . | Cumulative incidence after 15 y (95% CI) . |
|---|---|---|---|
| CRT (frontline therapy) | P = .044 | ||
| None | 1388 (27.7) | 7 | 1.0% (0%-2.1%) |
| ≥ 12 Gy | 3618 (72.3) | 39 | 3.3% (1.1%-5.6%) |
| 12 Gy | 2015 | 11 | 1.6% (0-3.4%) |
| ≥ 18 Gy | 1603 | 28 | 3.3% (0.9-5.6%) |
| CRT (+ relapse therapy) | P = .048 | ||
| None | 1140 (22.8) | 7 | 1.2% (0.2-2.3%) |
| ≥ 12 Gy | 3866 (77.2) | 45 | 3.5% (1.5%-5.5%) |
| 12 Gy | 1779 | 11 | 1.7% (0.1-3.4%) |
| ≥ 18 Gy | 2087 | 34 | 3.2% (1.1-5.3%) |
SN = secondary neoplasm; CRT = cranial radiation therapy.
Frontline therapy: only patients with SN as first event.